NSPR
InspireMD, Inc.
NASDAQ · ILHealthcareMedical - Devices
$0.71+0.88%
Price as of Jul 20, 2026
NSPR ownership
InspireMD, Inc. ownership & insider activity
Latest available institutional positioning and SEC Form 4 insider transactions, coalesced at the company entity level when listings share coverage.
Insider Activity
Sentiment
66/100
Buys (3m)
11
Sells (3m)
14
Net (3m)
$176.3K
Insiders buyingCluster buying
Insider trades by month Buys Sells
Dec
Aug
Nov
Dec
Feb
May
Context3-month price -48%Institutions reducing (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 29, 2026 | Stuka Pauldirector | Buy | 20,000 | $0.88 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 7,186 | $2.51 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 5,132 | $2.46 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 9,923 | $2.55 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 10,000 | $3.65 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 3,760 | $2.51 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 7,073 | $2.51 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 2,941 | $1.59 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 2,454 | $2.51 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 1,572 | $2.51 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 3,660 | $2.46 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 2,476 | $2.61 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 22,778 | $1.01 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 3,858 | $2.71 |
| May 21, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 2,482 | $2.51 |
| May 15, 2026 | Stuka Pauldirector | Buy | 10,000 | $1.16 |
| May 15, 2026 | Stuka Pauldirector | Buy | 5,000 | $1.15 |
| May 13, 2026 | Slosman Marvindirector, officer: CEO and President | Buy | 21,000 | $1.20 |
| May 12, 2026 | Stuka Pauldirector | Buy | 10,000 | $1.19 |
| May 12, 2026 | Stuka Pauldirector | Buy | 65,626 | $1.16 |
| May 8, 2026 | Stuka Pauldirector | Buy | 6,378 | $1.15 |
| May 8, 2026 | ROUBIN GARY Sdirector | Buy | 90,000 | $1.18 |
| May 8, 2026 | Ward Scott R.director | Buy | 73,255 | $1.15 |
| May 8, 2026 | Ward Scott R.director | Buy | 15,995 | $1.15 |
| May 8, 2026 | Stuka Pauldirector | Buy | 1,517 | $1.12 |
| Feb 2, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 5,000 | $1.65 |
| Feb 2, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 12,395 | $1.65 |
| Feb 2, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 4,781 | $1.66 |
| Feb 2, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 8,411 | $1.57 |
| Feb 2, 2026 | Gleason Shane Thomasofficer: Chief Commercial Officer | Sell | 17,593 | $1.62 |
Source: NSPR SEC Form 4 filings, latest May 29, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their NSPR positions over the last 6 months (SEC Form 13F).
Increased
11
New positions
14
Reduced
16
Sold out
23
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| ROSALIND ADVISORS, INC. | Unchanged | 3.9M | Feb 12, 2026 |
| ROSALIND ADVISORS, INC. | Unchanged | 3.9M | May 14, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Unchanged | 3.4M | May 15, 2026 |
| NANTAHALA CAPITAL MANAGEMENT, LLC | Unchanged | 3.4M | Feb 13, 2026 |
| ABRDN PLC | Unchanged | 3.2M | Apr 29, 2026 |
| ORBIMED ADVISORS LLC | Unchanged | 3.1M | May 15, 2026 |
| ORBIMED ADVISORS LLC | Increased | 3.1M | Feb 17, 2026 |
| PARKMAN HEALTHCARE PARTNERS LLC | Reduced | 2.4M | Feb 17, 2026 |
| PARKMAN HEALTHCARE PARTNERS LLC | Unchanged | 2.4M | May 15, 2026 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | Unchanged | 2.1M | Feb 13, 2026 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | Reduced | 2.1M | May 15, 2026 |
| MARSHALL WACE, LLP | Unchanged | 1.9M | May 15, 2026 |
| MARSHALL WACE, LLP | Unchanged | 1.9M | Feb 13, 2026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | Reduced | 1.1M | Feb 12, 2026 |
| SOLEUS CAPITAL MANAGEMENT, L.P. | Reduced | 1.0M | May 14, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.